Is HER2 targeting on the horizon in urothelial carcinoma? 

Join Dr Vadim Koshkin as he answers a series of questions focused on the potential for targeting HER2 in the treatment of urothelial carcinoma, including the rationale for HER2 as a target, approaches to HER2 testing, the latest data on emerging HER2-targeted therapies and the potential implications for future clinical practice.
Find out more here: touchoncologyi...
This activity is funded by an independent medical education grant from Seagen Inc. This activity is jointly provided by USF Health and touchIME.
#GenitourinaryCancers#BladderCancer
#MolecularTesting
#HER2
#Cancer
#Carcinoma
#Urothelial